<DOC>
	<DOCNO>NCT00445029</DOCNO>
	<brief_summary>The current knowledge pathophysiology allergic contact dermatitis base murine model . In model , CD8+ T cell effector cell , CD4+ T cell regulate response limit expansion CD8+ T cell . The goal study characterize pathophysiology contact dermatitis , patient allergic para-phenylenediamine ( PPD ) . We suppose CD8+ T cell effector allergic contact dermatitis , although regulator cell belong LT CD4+ population . We test hypothesis blood sample , cutaneous biopsy patient allergic PPD .</brief_summary>
	<brief_title>Pathophysiological Study Allergic Contact Dermatitis Para-Phenylenediamine ( PPD ) . Analysis Cellular Molecular Targets Skin Inflammation</brief_title>
	<detailed_description />
	<mesh_term>Inflammation</mesh_term>
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Dermatitis , Contact</mesh_term>
	<mesh_term>Dermatitis , Allergic Contact</mesh_term>
	<criteria>For group : Patients age 18 65 year old . Both gender eligible study . Female participant must use contraceptive method . Feasibility patch test . Participants must able understand sign Informed Consent , comply aspect protocol . Patients must register social security system health insurance coverage  First group : allergic patient Patients allergic contact dermatitis paraphenylenediamine ( PPD ) base history PPD contact dermatitis positive PPD patch test .  Second group : healthy volunteer No history PPD allergic contact dermatitis , negative PPD patch test . Pregnant lactating woman . Evolutive skin disease test zone ( low back ) . Patients clinically significant disease ( chronic , recurrent active ) . Systemic corticotherapy immunosuppressive treatment previous month , local corticoid treatment week patch testing . Local systemic drug use interact outcome measure . Exposure sun UV radiation , 15 day patch test . Patients deprive civic right , custody , subject tutorial , judiciary administrative decision . Patients subject protection measure . Patients critical medical situation . Patients personal situation judge investigator unlikely compatible optimal participation study , could constitute risk patient . Linguistic barrier psychological profile prevent patient sign consent form . Patient still exclusion period follow participation another clinical trial . Patients earn 4500€ indemnity participation clinical trial previous 12 month , include study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2007</verification_date>
	<keyword>Allergic contact dermatitis</keyword>
	<keyword>para-phenylenediamine</keyword>
	<keyword>effector cell</keyword>
	<keyword>regulatory cell</keyword>
	<keyword>pathophysiology</keyword>
</DOC>